Shots:

• The new analysis from the clinical trial data evaluates Livmarli (IBAT inhibitor) vs natural history cohort in patients with alagille syndrome. The extensive real-world analysis conducted by GALA & results was presented at AASLD 2021
• The results showed a high improvement in 6yrs. event-free survival, 70% overall reduction for clinical outcomes with Livmarli, improvements in transplant-free survival & helps to support the impact of LIVMARLI in the patient population
• Livmarli has received the BTD for ALGS & PFIC type 2 and ODD for ALGS, PFIC & biliary atresia while MAA is currently under review. The company plans to launch the therapy in the EU in H2’22, if approved by EMA

  Ref: Businesswire | Image: Businesswire